ONCOS Stock Overview A biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. More details
Rewards Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Oncopeptides AB (publ) Competitors Price History & Performance
Summary of share price highs, lows and changes for Oncopeptides Historical stock prices Current Share Price SEK 11.13 52 Week High SEK 42.51 52 Week Low SEK 11.01 Beta -0.61 1 Month Change 0% 3 Month Change -1.59% 1 Year Change n/a 3 Year Change -91.38% 5 Year Change n/a Change since IPO -91.40%
Recent News & Updates
An undisclosed buyer acquired an 9.166336% stake in Oncopeptides AB (publ) (OM:ONCO) from Industrifonden for SEK 22.4 million. Jul 04
Oncopeptides AB (publ) Presents New Data Highlighting Treatment Benefits of Pepaxti in High-Risk Multiple Myeloma Patients at the COMy Congress May 17
Oncopeptides AB (Publ) Provides Sales Guidance for the First Quarter of 2024 Apr 04 Oncopeptides AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 300 million. Mar 13
Oncopeptides AB (publ), Annual General Meeting, May 22, 2024 Feb 24
Oncopeptides Announces European Commission Decides to Formally Approve its Application to EMA for Extended Indication for Pepaxti into Earlier Lines Dec 16 See more updates
An undisclosed buyer acquired an 9.166336% stake in Oncopeptides AB (publ) (OM:ONCO) from Industrifonden for SEK 22.4 million. Jul 04
Oncopeptides AB (publ) Presents New Data Highlighting Treatment Benefits of Pepaxti in High-Risk Multiple Myeloma Patients at the COMy Congress May 17
Oncopeptides AB (Publ) Provides Sales Guidance for the First Quarter of 2024 Apr 04 Oncopeptides AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 300 million. Mar 13
Oncopeptides AB (publ), Annual General Meeting, May 22, 2024 Feb 24
Oncopeptides Announces European Commission Decides to Formally Approve its Application to EMA for Extended Indication for Pepaxti into Earlier Lines Dec 16
Oncopeptides AB (publ) to Report Q3, 2024 Results on Nov 07, 2024 Nov 18
Oncopeptides Selects to Present Additional Data from Ocean Study Nov 15
Oncopeptides AB (publ) to Report Q2, 2024 Results on Aug 14, 2024 Oct 27
Oncopeptides AB (publ) Announces the Nomination Committee Oct 21
Oncopeptides AB (publ) to Report Q1, 2024 Results on May 03, 2024 Oct 12
Oncopeptides AB (publ) to Report Fiscal Year 2023 Final Results on Apr 22, 2024 Oct 02
Oncopeptides AB (publ) to Report Fiscal Year 2023 Results on Feb 27, 2024 Sep 21
Oncopeptides AB (Publ) Announces Positive Opinion on Type II Variation to Extend the Therapeutic Indication of Pepaxti Based on Ocean Trial Results Sep 15
Oncopeptides AB (publ) Appoints Henrik Bergentoft as Chief Financial Officer Aug 10 Oncopeptides AB (publ) Announces Sofia Heigis to Move from the CCO Role to CEO Role
Holger Lembrér Will Leave Oncopeptides as Chief Financial Officer Jun 14
Insufficient new directors Mar 27
Insufficient new directors Mar 09 Oncopeptides AB (publ) to Report Q2, 2023 Results on Aug 10, 2023
Oncopeptides AB (Publ) Announces Chief Financial Officer Changes Jan 12
Oncopeptides AB (publ) Announces Jakob Lindberg Assumes Chief Scientific Officer Jan 05
Oncopeptides AB (Publ) Announces Executive Changes Jan 04
Oncopeptides AB (publ) Announces Nomination Committee Appointments Dec 23
Oncopeptides AB (publ) to Report Fiscal Year 2022 Final Results on Apr 25, 2023 Dec 15
Oncopeptides Provides Update on Pepaxto US Marketing Authorization Dec 08
Insufficient new directors Nov 29
Oncopeptides AB (Publ) Announces Pepaxti Has Been Granted Marketing Authorization in the Uk Nov 12
Oncopeptides AB (Publ) Announces the Market Potential for Pepaxti in Europe Nov 11
Oncopeptides AB (publ), Annual General Meeting, May 25, 2023 Nov 09
Insufficient new directors Oct 26
Oncopeptides AB (publ) Announces Data from the Phase 3 Lighthouse Study Oct 26
Insufficient new directors Oct 12
Oncopeptides AB (publ) Starts Commercialization of Pepaxti in Europe - Germany First Market Oct 04
Oncopeptides AB (publ) Provides Update from Meeting with Advisory Committee ODAC Sep 23
Insufficient new directors Sep 21
Oncopeptides AB (Publ) Receives SEK 5 Million Grant for Nk-Cell Engager Project in Multiple Myeloma Sep 08
European Commission Approves Oncopeptides' Pepaxti for the Treatment of Patients with Relapsed Refractory Multiple Myeloma Aug 19
Forecast to breakeven in 2024 Aug 13
Insufficient new directors Aug 09
Oncopeptides AB (Publ) Issues A Positive Opinion Recommending Full Approval of Oncopeptides Peti in Eu for Patients with Tr Triple Class Refractory Multiple Myeloma Jun 25
Oncopeptides AB (Publ) Announces That the European Medicines Agency´S Committee for Medicinal Products for Human Use Jun 24
Insufficient new directors May 18
Insufficient new directors Mar 24
Insufficient new directors Mar 01
Oncopeptides AB (publ) to Report Fiscal Year 2022 Results on Feb 16, 2023 Feb 18
Oncopeptides Rescinds Voluntary Withdrawal of Pepaxto in the US – No Intent to Market in the US at This Time Jan 22
Oncopeptides AB (Publ) Announces Data from Phase 3 Ocean Study Published in the Lancet Haematology Jan 13
Oncopeptides AB (Publ) Presents Phase 3 Ocean Study Results At the IMW Meeting Sep 12
Oncopeptides AB (publ) Presents New Data from OCEAN and PORT Study - Abstracts Online Aug 28
Deputy CEO & CFO recently bought kr82k worth of stock Aug 25
No longer forecast to breakeven Jul 30
Oncopeptides' Pepaxto Receives Specific C-Code and Pass-Through Payment Status Further Streamlining Reimbursement in Hospital Sites of Care Jul 15
Forecast to breakeven in 2023 Jul 09
Insider recently bought kr200k worth of stock Jun 03 Oncopeptides AB Announces Positive Topline Results from the Head-To-Head Phase 3 Ocean Study Evaluating the Efficacy and Safety of Melflufen
Forecast breakeven pushed back to 2024 May 21
Oncopeptides AB (Publ) Presents Clinical Abstracts on Melflufen At the 2021 American Society of Clinical Oncology May 21
Oncopeptides AB (publ) Presents New Clinical and Preclinical Melflufen Data at the Upcoming European Hematology Association Meeting May 13
Oncopeptides AB Completes Patient Enrollment in Phase 2 Port Study May 06
Chief Scientific Officer recently sold kr16m worth of stock Mar 18
Oncopeptides Announces Commercial Availability of PEPAXTO® Mar 16
Oncopeptides AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 1.1218 billion. Mar 12
Oncopeptides AB (Publ) Announces Executive Changes Mar 09
Oncopeptides AB (publ) Receives U.S. Food and Drug Administration Approval for PEPAXTO for Patients with Relapsed or Refractory Multiple Myeloma Feb 27
New 90-day high: kr180 Feb 26 Oncopeptides AB (publ) to Report Q2, 2021 Results on Aug 26, 2021
Insider recently sold kr772k worth of stock Jan 20
Oncopeptides Enrolls the First Patient in the Phase 3 LIGHTHOUSE Combination Study in Multiple Myeloma Dec 23
Oncopeptides AB Appoints Linda Holmström as Director of Investor Relations Dec 17 Oncopeptides AB (Publ) Announces That the Pivotal Phase 2 HORIZON Study Evaluating Intravenous Melflufen (INN Melphalan Flufenamide) in Combination with Dexamethasone in Relapsed Refractory Multiple Myeloma, Has Been Published in the Peer-Reviewed Journal of Clinical Oncology Oncopeptides AB (publ) to Report Q1, 2021 Results on May 26, 2021
Oncopeptides AB (publ) Announces New Data for Melflufen Accepted for Presentation at the Annual American Society of Hematology Meeting Nov 06
Oncopeptides AB (publ) Submits Investigational New Drug application to FDA for the second drug candidate from the PDC platform Oct 19
Oncopeptides AB (publ) Intents to File for Conditional Approval of Melflufen with EMA Oct 13
Oncopeptides initiates U.S. Expanded Access Program with melflufen in triple-class refractory multiple myeloma Oct 04
Oncopeptides AB (publ) to Report Q3, 2020 Results on Nov 19, 2021 Aug 27
Oncopeptides AB (publ) to Report Fiscal Year 2020 Results on Feb 18, 2021 Aug 26
Oncopeptides AB (publ) to Report Q1, 2021 Results on May 26, 2021 Aug 16
Oncopeptides AB (publ) Announces Executive Changes, Effective July 1, 2020 Jul 02 Oncopeptides AB (publ) (OM:ONCO) agreed to acquire Kancera's drug development facility in Solna, Sweden. Jun 30
Shareholder Returns ONCOS GB Biotechs GB Market 7D 0% 1.4% 1.2% 1Y n/a -23.8% 4.3%
See full shareholder returns
Return vs Industry: Insufficient data to determine how ONCOS performed against the UK Biotechs industry .
Return vs Market: Insufficient data to determine how ONCOS performed against the UK Market .
Price Volatility Is ONCOS's price volatile compared to industry and market? ONCOS volatility ONCOS Average Weekly Movement n/a Biotechs Industry Average Movement 9.1% Market Average Movement 4.7% 10% most volatile stocks in GB Market 10.6% 10% least volatile stocks in GB Market 2.5%
Stable Share Price: ONCOS has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ONCOS's volatility change over the past year.
About the Company Oncopeptides AB (publ), a biotech company, engages in the commercialization, and research and development of treatments for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is melflufen, a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden
Show more Oncopeptides AB (publ) Fundamentals Summary How do Oncopeptides's earnings and revenue compare to its market cap? ONCOS fundamental statistics Market cap SEK 942.15m Earnings (TTM ) -SEK 310.39m Revenue (TTM ) SEK 9.48m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) ONCOS income statement (TTM ) Revenue SEK 9.48m Cost of Revenue SEK 17.00k Gross Profit SEK 9.46m Other Expenses SEK 319.85m Earnings -SEK 310.39m
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
Aug 10, 2023
Earnings per share (EPS) -3.29 Gross Margin 99.82% Net Profit Margin -3,274.49% Debt/Equity Ratio 0%
How did ONCOS perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2023/06/24 10:23 End of Day Share Price 2023/03/27 00:00 Earnings 2023/03/31 Annual Earnings 2022/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Oncopeptides AB (publ) is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Erik Hultgård Carnegie Investment Bank AB Patrik Ling DNB Markets Peter Welford Jefferies LLC
Show 3 more analysts 